Cardiovascular Risk Factors in the Antiphospholipid Syndrome
A major cause of morbidity and mortality in the context of the antiphospholipid syndrome (APS) is the occurrence of thrombotic events. Besides the pathogenic roles of antiphospholipid antibodies (aPL), other risk factors and medical conditions, which are conditions for traditional risk of an individ...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2014-01-01
|
| Series: | Journal of Immunology Research |
| Online Access: | http://dx.doi.org/10.1155/2014/621270 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832559329547386880 |
|---|---|
| author | Felipe Freire da Silva Roger Abramino Levy Jozélio Freire de Carvalho |
| author_facet | Felipe Freire da Silva Roger Abramino Levy Jozélio Freire de Carvalho |
| author_sort | Felipe Freire da Silva |
| collection | DOAJ |
| description | A major cause of morbidity and mortality in the context of the antiphospholipid syndrome (APS) is the occurrence of thrombotic events. Besides the pathogenic roles of antiphospholipid antibodies (aPL), other risk factors and medical conditions, which are conditions for traditional risk of an individual without the APS, can coexist in this patient, raising their risk of developing thrombosis. Therefore, the clinical and laboratory investigation of comorbidities known to increase cardiovascular risk in patients with antiphospholipid antibody syndrome is crucial for the adoption of a more complete and effective treatment. Experimental models and clinical studies show evidence of association between APS and premature formation of atherosclerotic plaques. Atherosclerosis has major traditional risk factors: hypertension, diabetes mellitus, obesity, dyslipidemia, smoking, and sedentary lifestyle that may be implicated in vascular involvement in patients with APS. The influence of nontraditional risk factors as hyperhomocysteinemia, increased lipoprotein a, and anti-oxLDL in the development of thromboembolic events in APS patients has been studied in scientific literature. Metabolic syndrome with all its components also has been recently studied in antiphospholipid syndrome and is associated with arterial events. |
| format | Article |
| id | doaj-art-1640fd9621b94f05a12d5486c1a1984c |
| institution | Kabale University |
| issn | 2314-8861 2314-7156 |
| language | English |
| publishDate | 2014-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Journal of Immunology Research |
| spelling | doaj-art-1640fd9621b94f05a12d5486c1a1984c2025-02-03T01:30:12ZengWileyJournal of Immunology Research2314-88612314-71562014-01-01201410.1155/2014/621270621270Cardiovascular Risk Factors in the Antiphospholipid SyndromeFelipe Freire da Silva0Roger Abramino Levy1Jozélio Freire de Carvalho2Escola Bahiana de Medicina e Saúde Pública, 40290-000 Salvador, BA, BrazilRheumatology Division, Universidade Estadual do Rio de Janeiro, 20550-900 Rio de Janeiro, RJ, BrazilRheumatology Division, Centro Médico do Hospital Aliança, 41810-080 Salvador, BA, BrazilA major cause of morbidity and mortality in the context of the antiphospholipid syndrome (APS) is the occurrence of thrombotic events. Besides the pathogenic roles of antiphospholipid antibodies (aPL), other risk factors and medical conditions, which are conditions for traditional risk of an individual without the APS, can coexist in this patient, raising their risk of developing thrombosis. Therefore, the clinical and laboratory investigation of comorbidities known to increase cardiovascular risk in patients with antiphospholipid antibody syndrome is crucial for the adoption of a more complete and effective treatment. Experimental models and clinical studies show evidence of association between APS and premature formation of atherosclerotic plaques. Atherosclerosis has major traditional risk factors: hypertension, diabetes mellitus, obesity, dyslipidemia, smoking, and sedentary lifestyle that may be implicated in vascular involvement in patients with APS. The influence of nontraditional risk factors as hyperhomocysteinemia, increased lipoprotein a, and anti-oxLDL in the development of thromboembolic events in APS patients has been studied in scientific literature. Metabolic syndrome with all its components also has been recently studied in antiphospholipid syndrome and is associated with arterial events.http://dx.doi.org/10.1155/2014/621270 |
| spellingShingle | Felipe Freire da Silva Roger Abramino Levy Jozélio Freire de Carvalho Cardiovascular Risk Factors in the Antiphospholipid Syndrome Journal of Immunology Research |
| title | Cardiovascular Risk Factors in the Antiphospholipid Syndrome |
| title_full | Cardiovascular Risk Factors in the Antiphospholipid Syndrome |
| title_fullStr | Cardiovascular Risk Factors in the Antiphospholipid Syndrome |
| title_full_unstemmed | Cardiovascular Risk Factors in the Antiphospholipid Syndrome |
| title_short | Cardiovascular Risk Factors in the Antiphospholipid Syndrome |
| title_sort | cardiovascular risk factors in the antiphospholipid syndrome |
| url | http://dx.doi.org/10.1155/2014/621270 |
| work_keys_str_mv | AT felipefreiredasilva cardiovascularriskfactorsintheantiphospholipidsyndrome AT rogerabraminolevy cardiovascularriskfactorsintheantiphospholipidsyndrome AT jozeliofreiredecarvalho cardiovascularriskfactorsintheantiphospholipidsyndrome |